Gvoke Pfs 1-Pack Syringe (glucagon)
Glucagon and Analogs Subcutaneous Syringe (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Glucagon, an antihypoglycemic agent, is a hormone synthesized and secreted by the alpha2 cells of the pancreatic islets of Langerhans that increases blood glucose concentration by stimulating hepatic glycogenolysis.
USES: This medication is the same as your body's own glucagon, a natural substance that raises blood sugar by causing the body to release sugar stored in the liver. It is used to treat very low blood sugar (hypoglycemia) that may cause you to need help from others. Make sure a family member or caregiver knows where you keep this medication and how to use it before you need help.
Generic name: glucagon
Pronunciation: (GLOO-ka-gon)
Drug class: Glucagon and Analogs
Therapeutic class: Endocrine
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Gvoke Pfs 1-Pack Syringe
Indications
The following indications are listed for Gvoke Pfs 1-Pack Syringe:
- Hypoglycemic Disorder
Also known as: Hypoglycemia.
Dosing
Dosage of glucagon or glucagon hydrochloride is expressed in terms of glucagon.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Gvoke Pfs 1-Pk 1 Mg/0.2 Ml Syr | Maintenance | Inject 0.2 milliliter (1 mg) by subcutaneous route once in the abdomen, thigh, or upper arm may repeat in 15 minutes if inadequate response. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
Moderate Interaction: Assess the risk to the patient and take action as needed.
Glucagon, Dasiglucagon/Coumarin Anticoagulants
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Not defined.
CLINICAL EFFECTS: Excess hypoprothrombinemia and possible bleeding complications.
PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).
PATIENT MANAGEMENT: If the duration of glucagon/dasiglucagon therapy is one day, a clinically important interaction is unlikely. Avoid using multiple doses of glucagon/dasiglucagon in anticoagulated patients. If this combination is necessary, decrease the warfarin dose prior to glucagon/dasiglucagon dosing. Monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin and/or hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform INR to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.
DISCUSSION: If the duration of glucagon/dasiglucagon therapy is one day, a clinically important interaction is unlikely. However, the potentiation effects of glucagon/dasiglucagon on the anticoagulant effect of warfarin seems to occur rapidly and can reverse within one day of stopping glucagon.
Contraindications
There is no enhanced messaging for this drug.
- Insulinoma
- Pheochromocytoma
- Glucagonoma
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Acute respiratory distress syndrome
- Anaphylaxis
- Dyspnea
- Hypersensitivity drug reaction
- Hypertension
- Hypotension
- Necrolytic migratory erythema
More Frequent
- Headache disorder
- Injection site sequelae
- Nausea
- Vomiting
Less Frequent
- Acute abdominal pain
- Diarrhea
- Dizziness
- Drowsy
- General weakness
- Pallor
- Urticaria
Rare or Very Rare
- Hyperglycemia
- Skin rash
- Tachycardia
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Hypoglycemic disorder | ||
| E08.64 | ICD10CM | Diabetes mellitus due to underlying condition with hypoglycemia |
| E08.649 | ICD10CM | Diabetes mellitus due to underlying condition with hypoglycemia without coma |
| E09.64 | ICD10CM | Drug or chemical induced diabetes mellitus with hypoglycemia |
| E09.649 | ICD10CM | Drug or chemical induced diabetes mellitus with hypoglycemia without coma |
| E10.64 | ICD10CM | Type 1 diabetes mellitus with hypoglycemia |
| E10.649 | ICD10CM | Type 1 diabetes mellitus with hypoglycemia without coma |
| E11.64 | ICD10CM | Type 2 diabetes mellitus with hypoglycemia |
| E11.649 | ICD10CM | Type 2 diabetes mellitus with hypoglycemia without coma |
| E13.64 | ICD10CM | Other specified diabetes mellitus with hypoglycemia |
| E13.649 | ICD10CM | Other specified diabetes mellitus with hypoglycemia without coma |
| E16.0 | ICD10CM | Drug-induced hypoglycemia without coma |
| E16.1 | ICD10CM | Other hypoglycemia |
| E16.2 | ICD10CM | Hypoglycemia, unspecified |
| P70.3 | ICD10CM | Iatrogenic neonatal hypoglycemia |
| P70.4 | ICD10CM | Other neonatal hypoglycemia |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.